Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS009 monotherapy and triple combination in advanced malignancies
NCT05650203Phase 1Withdrawn
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Mar 2023
- Primary completion
- Oct 2025
01
Overview
Phase 1, open-label trial of JS009 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), endometrial cancer (EC) and 2 more, sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoint: Dose-Limiting Toxicity at 42 days. Planned start Mar 2023; status: withdrawn.
02
Drugs
JS009
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)endometrial cancer (EC)ovarian cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05650203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05650203.